Attendees will receive knowledge on important and essential requirements related to Risk Management for potential pharmaceutical adverse effects. This webinar will provide
Course Objectives:
• Risk Management and Risk Minimization Action Plans 2005
• Consequences of FDAAA 2007
• Understanding the impact
• Assessing the potential need for a REMS
• Responding to a requirement for a REMS
• Voluntary submission of a REMS
• Implementing a REMS
Background:
Pharmaceutical and biologic products often have untoward effects in patient populations. The FDA requires that a plan
Why Should You Attend:
Pharmaceutical and biologic products may have adverse effects. This can be observed either in general or in specific patient populations. Adverse effects may be related to class and structure and may be observed after approval of the drug. Strategies must be in place if a pharmaceutical or biologic product is deemed to likely have or is observed to exhibit a harmful response in addition to the health benefit. To assure public safety, the FDA requires implementation of a plan designed to mitigate the risk. These plans are developed as part of a risk evaluation and mitigation strategy (REMS).
Course Outline:
• FDAAA and risk management
• Assessing the need for REMS
• REMS and adverse effects
• Contributing factors
• Preparing a REMS
• Communication
• Submission timeline
• Implementation
• Patient registration
What You Get:
• Training Reference Materials
• Live Q&A with our Expert
• Participation Certificate
• Access to Signup Community (Optional)
• Reward Points
Who Will Benefit:
• Regulatory Affairs
• Compliance
• Clinical Research Administrators
• Study Sponsors
• Legal
• Senior Management (production, supply chain
• Pharmacovigilance
• Medical Affairs
• Clinical Development
• Clinical Affairs
• Clinical Research
• Pharmacists
• Biostatisticians
Microbiological and Business Risk of not Testing Raw Materials for Microbial Presence
Get Instant Access 60 Minutes View Program |
Bioavailability and Bioequivalence Studies submitted in NDAs and INDs
Get Instant Access 90 Minutes View Program |
Veterinary Feed Directive (VFD) Final Rule – What you need to know?
Get Instant Access 60 Minutes View Program |
Packaging and Labeling for Commercial and Clinical Products
Get Instant Access 90 Minutes View Program |
Providing DMFs in eCTD format
Get Instant Access 90 Minutes View Program |
Get Instant Access On-Demand Access
Preparing for the ICE Storm: What to Do During I 9 Audits and ICE Raids
Janette S. Levey
Human Resources
Get Instant Access On-Demand Access
OSHA Inspections and Investigations-How to Manage Them
Irwin Dobrushin
Environment Health and Safety | OSHA
Get Instant Access On-Demand Access
29 CFR 1904: OSHA's New Injury Recordkeeping E-Submission Rule
Occupational Safety and Health Administration
Get Instant Access On-Demand Access
Working with Excel Databases: Sort, Filter, Subtotal and More
Cathy Horwitz
Cross Industry | Skill Enhancement
Get Instant Access On-Demand Access
Writing Audit Reports
Jonnie T. Keith CIA, CFE, CGAP, CICA
Governance, Risk and Compliance
Get Instant Access On-Demand Access
BSA Reporting Requirements
Banking and Financial Services Industry
Get Instant Access On-Demand Access
Human Factors-Usability Based on ISO 62366
Medical Device | Diagnostic | Pharmaceutical | Biologics fields
Get Instant Access On-Demand Access
Chat GPT for Project Managers
Charles H. Paul
All FDA Regulated Industry